This 3-part webinar series will help you gain a better understanding of the science and language involved in EGFR NSCLC testing and strategies to help lead to better outcomes.
Progression. Now What? Necessary Testing, Common Mechanisms of EGFR-Dependent Resistance, and Possible Treatment Strategies
Review necessary biomarker testing that should be conducted upon disease progression.
Consider the pros/cons of liquid biopsy.
Discuss common mechanisms of EGFR‐dependent resistance (e.g., C797S) that occur on 1st and 2nd generation EGFR TKI therapies, including osimertinib.
Explore treatments and clinical trials that may offer benefit for progression from common EGFR‐ dependent post‐osimertinib mutations.
Weigh treatment considerations if CNS disease is still under control on osimertinib.
Joshua Bauml, MD
Melina Marmarelis, MD, MSCE
I Have Another Oncogene Driver! What Are the Implications of This?
Outline other oncogene driver mutations that may be found upon progression (e.g., MET amplification, RET fusion, BRAF, HER2, etc.).
Explore treatments and clinical trials that may offer benefit for progression associated with secondary, non‐EGFR driver mutations.
Zofia Piotrowska, MD
Catherine Meador, MD, PhD
What is Histological Transformation, and Can it be Treated?
Discuss histological transformations that may occur after treatment with EGFR TKIs, including small cell and squamous cell.
Explore treatments and clinical trials that may offer benefit for progression associated with histological transformation.
Helena A. Yu, MD
Joseph Chan, MD, PhD
Meet the Moderators
My name is Ivy Elkins and I was diagnosed at age 47 with EGFR-positive stage IV lung cancer that had metastasized to my bones and brain. I have been treated successfully with targeted therapy medications since my diagnosis, thus allowing me to lead an active life and handle my lung cancer as a chronic disease. I receive my treatment at the University of Chicago and live in the Chicago suburbs with my husband Ben and my two teenaged boys. I have an undergraduate degree in English from Princeton University and a Master’s in Business Administration from the Wharton School at the University of Pennsylvania.
My journey with lung cancer started long before I became a patient. When I was 13 years old, I lost two grandparents and my dad to lung cancer within a period of eight months. Fourteen years later, my mom and close aunt succumbed to the disease within a two-year period. I needed to find a way to redirect my anger into action so I became a volunteer and advocate for lung cancer. Then, as president of LUNGevity Foundation the unthinkable happened. In 2009, at 39 years old with four small children, I was diagnosed with lung cancer.
To learn more about our moderators and the other founding members of EGFR Resisters, you can visit their website at egfrcancer.org.
Slides for "Progression. Now What?"
Slides for "I Have Another Oncogene Driver!"
Slides for "What is Histological Transformation and Can it be Treated?"
Real Patients, Real Stories
I was diagnosed with stage iiib non-small cell adenocarcinoma lung cancer in April 2014. I was only 30 years old. I was working full-time in the business development department at my local ford dealership and had no clue what was coming ahead of me...(cont.) Diane, 37
I was first diagnosed with suspected stage I NSCLC in April 2013 at age 46. In hindsight, symptoms had been smoldering for several years but I put them down to other causes. For several winters, I noticed that I was getting short of breath more easily with activities but having had asthma since my teens, I simply wrote it off as “my asthma is getting worse as I get older.”...(cont.) Dan, 54
At the age of 54 I started to worry about the crepey skin on my neck. I’d bought a special moisturizer and slathered it on my face and neck hoping to slow down the aging process. During the first week of June of 2013 I felt a lump above my right clavicle during my morning routine...(cont.) Beth, 62